Braidwell »

Oruka Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Oruka Therapeutics (ORKA) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Oruka Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Oruka Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Oruka Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2024-09-30 $13M 516k 24.51

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Cg Oncology (CGON)
Nuvasive Note 0.375% 3/1 (Principal)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Neogenomics Note 0.250% 1/1 (Principal)
Apogee Therapeutics (APGE)
Apellis Pharmaceuticals (APLS)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Align Technology (ALGN)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)

View all positions for Braidwell

Top funds holding Oruka Therapeutics

Fairmount Funds Management
VR Adviser
Commodore Capital
Perceptive Advisors
Avidity Partners Management
Franklin Resources
Paradigm Biocapital Advisors
Braidwell
Dr. Jeffrey R. Jay, M.D.
Point72 Asset Management
Frazier Life Sciences Management
Redmile Group
Woodline Partners
Affinity Asset Advisors
Driehaus Capital Management

View all funds holding Oruka Therapeutics